Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials -

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Information type: Randomised controlled trials
Source: The Lancet
Specialities: Allergy and immunology | Ear, nose and throat disorders
Summary
Studies (total n=724) found dupilumab significantly reduced nasal polyp size vs. placebo (−2.06; 95% CI −2.43 to −1.69, p<0.0001 in SINUS-24 and −1.80; 95% CI −2.10 to −1.51, p<0.0001 in SINUS-52) and improved sinus opacification & severity of symptoms.
UKMi comment
A related commentary states these results support the benefits of adding dupilumab to daily standard of care for patients with severe severe chronic rhinosinusitis with nasal polyps, who otherwise have few therapeutic options.
Related links: Commentary